Journal ArticleDOI
4. Modelling Survival Data in Medical Research
About:
This article is published in Journal of The Royal Statistical Society Series A-statistics in Society.The article was published on 1995-01-01. It has received 1092 citations till now. The article focuses on the topics: Medical research.read more
Citations
More filters
Journal ArticleDOI
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
Meletios A. Dimopoulos,Michael Wang,Vladimir Maisnar,Jiri Minarik,William I. Bensinger,Maria-Victoria Mateos,Mihaela Obreja,Julie Blaedel,Philippe Moreau +8 more
TL;DR: The improved PFS HR at 18 months and the continued increase in CR rates for KRd through 18 cycles suggest that there may be a benefit of continued carfilzomib treatment.
Journal ArticleDOI
Survival Analysis of Breast Cancer Patients using Cox and Frailty Models
TL;DR: Both of the frailty and CPH model emphasis that the early detection of BC improves survival in BC patients, and both showed that, tumor characteristics and number of involved lymph nodes increase the mortality hazard of BC.
BookDOI
Handbook of Statistics in Clinical Oncology, Second Edition
John Crowley,Antje Hoering +1 more
Journal ArticleDOI
DegreeCox – a network-based regularization method for survival analysis
André Veríssimo,Arlindo L. Oliveira,Arlindo L. Oliveira,Marie-France Sagot,Marie-France Sagot,Susana Vinga +5 more
TL;DR: DegreeCox is a method that applies network-based regularizers to infer Cox proportional hazard models, when the features are genes and the outcome is patient survival, and is proposed to use network centrality measures to constrain the model in terms of significant genes.
Journal ArticleDOI
Glycemia, Insulin Resistance, Insulin Secretion, and Risk of Depressive Symptoms in Middle Age
Tasnime N. Akbaraly,Meena Kumari,Jenny Head,Karen Ritchie,Marie-Laure Ancelin,Adam G. Tabak,Eric J. Brunner,Isabelle Chaudieu,Michael Marmot,Jane E. Ferrie,Martin J. Shipley,Mika Kivimäki +11 more
TL;DR: Low insulin secretion appears to be a risk factor for DepS in middle-aged women, although further work is required to confirm this finding.
References
More filters
Journal ArticleDOI
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Geoffrey A. Block,Preston S. Klassen,J. Michael Lazarus,Norma J. Ofsthun,Edmund G. Lowrie,Glenn M. Chertow +5 more
TL;DR: Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization, and the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperph phosphatemia.
Journal ArticleDOI
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Roberto Pili,Georg A. Bjarnason,Xavier Garcia-del-Muro,Jeffrey A. Sosman,Ewa Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin +18 more
TL;DR: Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
Journal ArticleDOI
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote,Claes G. Tropé,Frédéric Amant,G.B. Kristensen,Tom Ehlen,N Johnson,René H.M. Verheijen,Maria E. L. van der Burg,A. J. Lacave,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Corneel Coens,Leen Verleye,Gavin Stuart,Sergio Pecorelli,Nicholas Reed +17 more
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Journal ArticleDOI
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
TL;DR: Five prognostic factors for predicting survival were identified and used to categorize patients with metastatic RCC into three risk groups, for which the median survival times were separated by 6 months or more.